Product Code: IRTNTR7566
About liver diseases
Liver diseases are of different types such as hepatitis, liver cancer, non-alcoholic fatty liver disease, and liver cirrhosis. Hepatitis is the largest segment among these diseases, of which hepatitis C is the biggest and fastest growing segment. The liver diseases caused by viral infections, alcoholism, obesity, diabetes, among many other reasons. Some of the diseases are not curable such as liver cirrhosis or non-alcoholic fatty liver disease, and are usually not diagnosed early. This leads to the substantial damage of the liver, which proves to be life-threatening. Some types of hepatitis are preventable or treatable by using vaccines and indicated drugs.
Technavio's analysts forecast the global liver diseases therapeutics market to grow at a CAGR of 15.61% over the period 2014-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the global liver diseases therapeutics market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of liver diseases.
Based on disease indication, the market is segmented as follows:
- Non-alcoholic fatty liver disease (includes non-alcoholic steatohepatitis)
- Liver cirrhosis
- Liver cancer
- Hepatitis (Hepatitis A, B, and C)
This report includes a discussion of the market in the following three regions:
- Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
- EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
- APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India.
Technavio's report, Global Liver Diseases Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the global liver diseases therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key regions
Key vendors
- F. Hoffmann-La Roche
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Merck
Other Prominent Vendors
- AbbVie
- Achillion Pharmaceuticals
- Advinus
- Angion Biomedica
- AstraZeneca
- Bayer
- BiOrion
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celsion
- Conatus
- Digna Biotech
- Dynavax Technologies
- Eli Lilly
- Galectin Therapeutics
- Genfit
- GenKyoTex
- Isis Pharmaceuticals
- Janssen Pharmaceuticals
- Kaketsuken
- La Jolla Pharmaceutical
- LG Life Sciences
- Mitsubishi Tanabe Pharma
- Nitto Denko
- Novartis
- Onyx Pharmaceuticals
- Phenex Pharmaceuticals
- Promedior
- Promethera Biosciences
- ProMetic Life Sciences
- Raptor Pharmaceuticals
- Shenzhen Kangtai Biological Products
- TCM Biotech
- Tobira Therapeutics
- VBL Therapeutics
- Verva Pharmaceuticals
- Virobay
- Zafgen
Key market driver
- Increased prevalence of liver diseases
- For a full, detailed list, view our report
Key market challenge
- Multiple patent expiries
- For a full, detailed list, view our report
Key market trend
- Growing public awareness
- For a full, detailed list, view our report
Key questions answered in this report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
Market overview
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
- Hepatitis
- Liver cancer
- Liver cirrhosis
- Nonalcoholic fatty liver disease
PART 06: Market landscape
- Global liver diseases therapeutics market
PART 07: Market segmentation by disease
- Hepatitis
- Liver cirrhosis
- Liver cancer
- Nonalcoholic fatty liver disease
PART 08: Global hepatitis therapeutics market
- Global hepatitis A therapeutics market
- Global hepatitis B therapeutics market
- Global hepatitis C therapeutics market
PART 09: Global liver cancer therapeutics market
PART 10: Global nonalcoholic fatty liver disease therapeutics market
PART 11: Global liver cirrhosis therapeutics market
PART 12: Market segmentation by type of molecule
- Biologics
- Small molecules
PART 13: Geographical segmentation
- Liver diseases therapeutics market in Americas
- Liver diseases therapeutics market in EMEA
- Liver diseases therapeutics market in APAC
PART 14: Market drivers
PART 15: Impact of drivers
PART 16: Market challenges
PART 17: Impact of drivers and challenges
PART 18: Market trends
PART 19: Vendor landscape
- Competitive scenario
- Market share analysis 2014
- Other and future prominent vendors
PART 20: Key vendor analysis
- F. Hoffmann-La Roche
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Merck
PART 21: Appendix
- List of abbreviations
- Explore Technavio
List of Exhibits
- Exhibit 01: Product offerings
- Exhibit 02: Hepatitis: Mode of transmission and incubation period
- Exhibit 03: Various modes of transmission of hepatitis B viral infection
- Exhibit 04: Various modes of transmission of hepatitis C viral infection
- Exhibit 05: Worldwide endemicity of hepatitis A virus infection
- Exhibit 06: Worldwide endemicity of hepatitis B virus infection
- Exhibit 07: Prevalence of hepatitis B in US 2005-2013
- Exhibit 08: Prevalence of hepatitis C across regions
- Exhibit 09: Antibodies indicating hepatitis
- Exhibit 10: Tests for viral proteins and genetic material
- Exhibit 11: Screening tests for hepatitis C infection
- Exhibit 12: Recommended dosages and schedules of hepatitis A vaccines
- Exhibit 13: Global liver diseases therapeutics market 2014-2019 ($ billions)
- Exhibit 14: Five forces analysis
- Exhibit 15: Global liver diseases therapeutics market by disease 2014
- Exhibit 16: Global hepatitis therapeutics market 2014-2019 ($ millions)
- Exhibit 17: Global hepatitis A therapeutics market 2014-2019 ($ millions)
- Exhibit 18: Global hepatitis B therapeutics market 2014-2019 ($ millions)
- Exhibit 19: Global hepatitis C therapeutics market 2014-2019 ($ millions)
- Exhibit 20: Global hepatitis therapeutics market by type 2014
- Exhibit 21: Global liver cancer therapeutics market 2014-2019 ($ millions)
- Exhibit 22: Global liver cancer therapeutics market: Challenges and drivers
- Exhibit 23: Global nonalcoholic fatty liver disease therapeutics market 2014-2019 ($ millions)
- Exhibit 24: Global nonalcoholic fatty liver disease therapeutics market: Challenges and drivers
- Exhibit 25: Global liver cirrhosis therapeutics market 2014-2019 ($ millions)
- Exhibit 26: Global liver cirrhosis therapeutics market: Challenges and drivers
- Exhibit 27: Global liver diseases therapeutics market by geography 2014
- Exhibit 28: Liver diseases therapeutics market in Americas ($ billions)
- Exhibit 29: Liver diseases therapeutics market in EMEA ($ billions)
- Exhibit 30: Liver diseases therapeutics market in APAC ($ billions)
- Exhibit 31: Impact of drivers
- Exhibit 32: Impact of drivers and challenges
- Exhibit 33: Johnson & Johnson: Business segmentation
